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Malignancies following Unmanipulated Haploidentical
Blood and Marrow Transplantation: Effects of CD341
Cell Dose and Disease Status
Ying-Jun Chang, Lan-Ping Xu, Dai-Hong Liu, Kai-Yan Liu, Wei Han, Yu-Hong Chen, Yu-Wang,
Huan Chen, Jing-Zhi Wang, Xiao-Hui Zhang, Xiang-Yu Zhao, Xiao-Jun HuangUnmanipulated haploidentical blood and marrow transplantation has been developed as an alternative trans-
plantation strategy for patients without an HLA-matched related or unrelated donor. In this transplantation
setting, factors associated with hematopoietic recovery have not been defined completely. The aim of this
study was to investigate the effects of donor and recipient characteristics on neutrophil and platelet engraft-
ment after unmanipulated HSCT. The study group comprised 348 patients who underwent unmanipulated
haploidentical blood and marrow transplantation to treat hematologic malignancy at a single institution be-
tween 2002 and 2007. Factors correlating with neutrophil and platelet engraftment posttransplantation were
analyzed retrospectively. All patients achieved an absolute neutrophil count ANC of 500/mL in a median of
13 days (range, 9 to 49 days). Of the 348 patients, 331 (95.11%) achieved an untransfused platelet count of.
20,000/mL in a median of 16 days (range, 7 to 356 days). Multivariate analysis showed that the amount of
CD341 cells infused (CD341 cells $ 2.19  106/kg recipient weight vs\ 2.19 106/kg recipient weight;
hazard ratio [HR] 5 1.695; 95% confidence interval [CI] 5 1.361 to 2.112; P\ .0001), and disease stage
(advanced vs early; HR 5 0.724; 95% CI 5 0.577 to 0.907; P 5 .005) were independently associated with
increased risk of platelet engraftment. Our results suggest that low numbers of CD341 cells in allografts
and advanced-stage disease may be critical factors associated with delayed platelet engraftment after unma-
nipulated haploidentical transplantation.
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Haploidentical stem cell transplantation (HSCT)
is an alternative transplantation strategy for patients
without a HLA-matched related or unrelated donor
[1-5]. One major issue that must be overcome for suc-
cessful HSCT is graft rejection [1,3]. Current and po-
tential strategies to overcome graft failure include
megadoses of CD341 donor cells, immunosuppressive
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[1,3,5]. Recently, we developed a new method for
HSCT that does not require in vitro T cell depletion.
This strategy,whichwe call theGIACprotocol, applies
sequential in vivo modulation of the recipient, the
donor T cell function, and the dose of donor hemato-
poeitic stem cells. The GIAC protocol entails the fol-
lowing: donor treatment with recombinant human
granulocyte colony-stimulating factor (rhG-CSF) to
induce donor immunologic tolerance; intensified
immunologic suppression to promote engraftment
and prevent graft-versus-host disease (GVHD); antith-
ymocyte immunoglobin (ATG) for GVHD and graft
rejection prophylaxis; and a combination of rhG-
CSF–primed bone marrow (G-BM) harvest and rhG-
CSF–mobilized peripheral blood stem cell (PBSC)
(G-PB) harvest to provide stem cell grafts. Under this
GIAC protocol, all patients achieved full engraftment;
the incidence of acute and chronic GVHDwas compa-
rable in the matched and mismatched cohorts [2,4-6].
In HLA-matched allogeneic and autologous
HSCT settings, multiple factors are associated with
Table 1. Patient, Donor, and Graft Characteristics
Number of patients 348
Recipient age at HSCT, years, median (range) 24 (2-54)
Recipient sex, n (%)
Male 224 (64.4%)
Female 124 (35.6%)
Recipient weight, kg, median (range) 64 (12-110)
Underlying disease, n (%)
Acute myelogenous leukemia 100 (28.7%)
Acute lymphoblastic leukemia 117 (33.6%)
Chronic myelogenous leukemia 105 (30.2%)
Myelodysplastic syndrome 17 (4.9%)
Others 9 (2.6%)
Disease status at transplantation, n (%)*
Early-stage disease 215 (61.8%)
Advanced-stage disease 133 (38.2%)
Time to transplantation after diagnosis, days,
median (range)
210 (58-7000)
Donor age at HSCT, years, median (range) 40 (14-67)
Sex match, n (%)
D male–R male 110 (31.6%)
D male–R female 57 (16.4%)
D female–R male 114 (32.8%)
D female–R female 67 (19.3%)
Donor type, n (%)
One locus mismatch 47 (13.5%)
Two loci mismatch 138 (39.7%)
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recipient sex matching, conditioning regimen, number
of CD341 cells infused, ABO mismatch, and numbers
of CD31 cells, CD81 cells, and subsets of CD341 cells
in the allograft [7-15]. The source of stem cells (bone
marrow or peripheral blood) also affects engraftment
kinetics, with PBSCs clearly associated with more
rapid recovery of both neutrophils and platelets. Few
published studies have investigated the effects of
HLA match, CD341 cell dose, and other patient and
donor characteristics on engraftment kinetics in recip-
ients of unmanipulated haploidentical blood and mar-
row grafts, however. We retrospectively analyzed data
from 348 recipients of unmanipulated haploidentical
blood and marrow allografts for patient, donor, and
graft factors that might affect engraftment kinetics.
We used factors identified from univariate analysis to
construct multivariate statistical models to identify
the variables that independently affected neutrophil
and platelet recovery in this HSCT protocol
[2,4,5,16].Three loci mismatch 163 (46.8%)
ABO compatibility, n (%)
Matched 188 (54%)
Major mismatched 69 (19.8%)
Minor mismatched 69 (19.8%)
Bidirectional mismatched 22 (6.3%)
Donor–recipient relationship, n (%)
Patient–child 194 (55.7%)
Sibling–sibling 108 (31.0%)
Child–patient 36 (10.3%)
Others 10 (2.9%)
Graft source, n (%)
G-PB + G-BM 348 (100%)
Infused CD3+ cells 108/kg recipient weight,
median (range)
1.64 (0.35-6.34)
Infused CD4+ cells 108/kg recipient weight,
median (range)
0.85 (0.19-3.81)
Infused CD8+ cells 108/kg recipient weight,
median (range)
0.63 (0.13-2.99)
Infused CD34+ cells 106/kg recipient weight,
median (range)
2.19 (0.83-9.69)
Conditioning regimen, n (%)
Modified busulfan/cyclophosphamide + ATG 348
GVHD prophylaxis, n (%)
CsA + ATG + MMF 348
*Disease status at transplantation was defined as described previously
[4,17].MATERIALS AND METHODS
Patient Population
Patients with hematologic malignancies suitable
for allogeneic HSCT without an HLA-identical re-
lated or unrelated donor were candidates for this study.
A total of 348 patients with malignant hematologic
disease who underwent unmanipulated HLA-
mismatched HSCT between October 2002 and De-
cember 2007 were enrolled.Written informed consent
was obtained from all patients and donors. The study
design was approved by the Institutional Review Board
of Peking University Institute of Hematology and the
Ethics Committee of Peking University People’s Hos-
pital. Table 1 summarizes characteristics of the 348
study patients [17].
Transplantation Procedure
All patients received a myeloablative conditioning
regimen comprising a combination of cytosine arabi-
noside 4 g/m2/day on days -10 and -9, busulfan
12 mg/kg given orally in 12 doses over 3 days (days
-8, -7, and -6), cyclophosphamide 1.8 g/m2/day on
days -5 and -4, simustine (Me-CCNU) 250 mg/m2
orally on day -3, and rabbit ATG (Thymoglobulin;
Sangstat, Fremont, CA) 2.5 mg/kg per day i.v. on
days -5 through -2 [4,5,18].
Donors received rhG-CSF (filgrastim) 5 mg/kg s.c.
once daily for 5 to 6 days. On the fourth day, bonemar-
row cells were harvested. The target total nucleated
cell count of 3.0  108 cells/kg recipient weight was
achieved (median, 3.51  108; range, 1.06 to 9.52 
108). On days 5 and 6, peripheral blood progenitor
cells (PBPCs) were collected using Fenwal CS3000(Fenwal Laboratories, Deerfield, IL) and Cobe Spec-
tra (Cobe Laboratories, Lakewood, CO) blood cell
separators. Anticoagulant citrate dextrose solution
(ACD-A) was used as the anticoagulant. The whole
blood:anticoagulant ratio was 11:1. The target mono-
nuclear cell count of 3.0  108 cells/kg recipient
weight was achieved (median, 3.49  108; range, 0.83
to 12.10  108) . The median volume pheresed was
12 L (range, 4.5 to 15 L). The fresh and unmanipulated
bone marrow and PBPCs collected on day 5 were in-
fused into the recipients. In those with advanced-stage
disease, a second apheresis was performed, and PBSCs
were cryopreserved for prophylaxis and treatment of
relapse [16,19].
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(CSA) and short-term methotrexate (MTX) with
mycophenolate mofetil (MMF). CSA was started on
day -9 at a dosage of 2.5 mg/kg i.v., with the switch
made to an oral formulation as soon as the patient
was able to take medication orally after engraftment.
A trough concentration of 150 to 300 ng/mL was
used to adjust the CSA dosage.MMFwas administered
orally, 0.5 g every 12 hours, from day -9 to day 30
posttransplantation, then 0.25 g twice daily for 1 to 2
months. The MTX dosage was 15 mg/m2 i.v. on day
1 and 10 mg/m2 on days 3, 6, and 11 posttransplanta-
tion. The diagnosis and grading of GVHD were done
according to published criteria [20-22]. Filgrastim
5 mg/kg/day s.c. was given to all recipients from day
6 posttransplantation until the neutrophil count
reached 0.5  109 cells/L for 3 consecutive days.
Bone marrow aspiration and cytogenetic studies were
performed at 1, 2, and 3 months after transplantation
to assess engraftment. HLADNA typing and polymer-
ase chain reaction DNA fingerprinting (short tandem
repeat) were used for donor chimerism detection.
For each patient, at least 2 tests were performed to
confirm donor chimerism [4,5,18].
Evaluation and Definitions
Engraftment was demonstrated by increasing neu-
trophil and platelet counts unsupported by transfu-
sions. Neutrophil engraftment after transplantation
was defined as an absolute neutrophil count (ANC)
exceeding 500/mL for 3 consecutive days. The first of
these 3 consecutive days was considered the day of
engraftment. Platelet recovery was defined as the
time after transplantation needed to achieve a blood
platelet count exceeding 20,000/mL without transfu-
sion support for 7 consecutive days. Graft failure was
defined as persistently decreasing peripheral blood
cell counts and progressive bone marrow hypoplasia
(\ 25% cellularity) occurring after documented
engraftment and in the absence of leukemic relapse,
drug toxicity, or infection and persisting for at least
14 days. The day of graft failure was assigned to the
day on which the ANC declined to\ 500/mL.
Statistical Analysis
Summary statistics, including proportions, means,
standard deviations, 95% confidence intervals (CIs),
medians, and ranges, were used to describe the patient
characteristics, pretransplantation variables, and post-
transplantation outcomes. The associations between
donor and recipient characteristics and hematopoietic
engraftment were analyzed using the Kaplan-Meier
method or calculated using the ‘‘cmprsk’’ library in
the R statistical package (University of Auckland;
http://www.r-project.org). The log-rank test was
used in survival analysis, and the Grey test was usedin cumulative incidence analyses. To confirm out-
comes and adjust for potential confounding factors,
multivariate Cox proportional hazardsmodels were as-
sessed for the proportional hazards assumption and for
testing interaction terms with covariates. Variables in-
cluded in the models were age (continuous;\vs$ the
median), sex, donor–patient sex match (female to male
vs others), ABO match (identical and minor vs major
and bidirectional), HLA match (1 locus vs 2 loci vs 3
loci), disease risk (high risk vs standard risk), CD34
dose (continuous;\ vs $ the median), and CD3 cell
dose (continuous; \ vs $ the median). The c2 test
and Mann-Whitney U test were used for categorical
variables and continuous variables, respectively. Cal-
culations were carried out using SPSS 13.0 statistical
software (SPSS Inc, Chicago, IL). R software was
used to calculate the cumulative incidence considering
the presence of competing risk.RESULTS
Neutrophil and Platelet Engraftment
All 348 patients achieved an ANC of 500/mL. The
median time to achieve an ANC. 500/mLwas 13 days
(range, 9 to 49 days), comparable to the times reported
previously in HLA-matched settings [23]. A total of
331 patients achieved an untransfused platelet count
of . 20,000/mL, in a median time of 16 days (range,
7 to 356 days). Seventeen patients failed to reach a sus-
tained platelet count of . 20,000/mL by the end of
follow-up; all of these patients received a transfusion
with irradiated whole blood-derived pooled platelets
(1 1011/unit). Eleven of these 17 patients died with-
out achieving platelet engraftment, at a median of
78 days (range, 33 to 260 days) posttransplantation.
The median numbers of cells infused wee as
follows: total nuclear cells, 7.33  108/kg (range,
2.40 to 17.85  108/kg); CD341 cells, 2.19  106/kg
(range, 0.83 to 9.69  106/kg); CD31 cells, 1.64 
108/kg (range, 0.35 to 6.34  108/kg); CD41 cells,
0.85  108/kg (range, 0.19 to 3.81  108/kg); CD81
cells, 0.63  108/kg (range, 0.13 to 2.99  108/kg).
The CD341 cell counts were 0.75  106/kg (range,
0.04 to 8.20  106/kg) in the bone marrow and
1.26  106/kg (range, 0.70-6.46  106/kg) in the pe-
ripheral blood components.
Recipient and Donor Characteristics Associated
with Engraftment
In this analysis (Table 2), the most prominent find-
ing was the association between the number of CD341
cells in the allograft and the degree of platelet engraft-
ment. Platelet engraftment was achieved by 161 of the
174 patients who received a CD341 cell dose\2.19
106/kg (92.5%) and by 170 of the 174 patients who re-
ceived a dose $ 2.19  106/kg (97.7%), for respective
Table 2. Univariate Analysis of the Factors Affecting Neutrophil and Platelet Engraftment in Patients with Hematologic
Malignancies after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation
Neutrophil Engraftment Platelet Engraftment
Variables HR 95% CI P HR 95% CI P
Recipient age 0.914 0.740–1.129 .405 0.777 0.625–0.965 .022
Sex 0.622 0.658–1.027 .084 0.927 0.739–1.162 .510
Weight 1.098 0.889–1.355 .386 0.931 0.750–1.156 .520
Disease status 0.824 0.660–1.030 .089 0.746 0.596–0.935 .011
Time to transplantation after diagnosis 0.813 0.657–1.005 .056 0.869 0.700–1.079 .202
HLA match 0.931 0.800–1.084 .356 0.838 0.720–0.975 .022
Patient–donor sex match 1.045 0.835–1.308 .702 1.008 0.802–1.268 .944
Donor age 0.927 0.749–1.146 .481 0.888 0.715–1.104 .285
Patient–donor ABO compatibility 1.019 0.801–1.296 .877 0.902 0.705–1.155 .414
Infused nuclear cells/kg recipient weight 1.018 0.950–1.092 .608 1.249 1.005–1.552 .045
Infused CD3+ cells/kg recipient weight 1.126 0.912–1.391 .270 1.140 0.918–1.415 .236
Infused CD4+ cells/kg recipient weight 1.084 0.877–1.339 .454 1.047 0.843–1.301 .675
Infused CD8+ cells/kg recipient weight, 1.037 0.839–1.281 .737 1.270 1.022–1.578 .031
Infused CD34+ cells/kg recipient weight 1.116 0.903–1.378 .309 1.632 1.312–2.031 < .0001
CMV antigenemia 1.222 0.987–1.513 .065 1.143 0.919–1.423 .230
HC 1.152 0.924–1.437 .208 1.017 0.813–1.272 .883
VOD 0.873 0.465–1.639 .673 0.839 0.432–1.628 .604
HR5 hazard ratio; CI5 confidence interval; HLA5 human leukocyte antigen; CMV5 cytomegalovirus; HC5 hemorrhagic cystitis; VOD5 hepatic
veno-occlusive disease.
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6 1.36% (P\ .001). The median time to achieve an
untransfused platelet count . 20,000/mL was signifi-
cantly shorter in the patients receiving a CD341 cell
dose $ 2.19 106/kg (14 days [range, 7 to 258 days]
vs 18.5 days [range, 9 to 356 days]; P\ .001).
Our findings also demonstrate the negative effects
of advanced disease on platelet recovery. Platelet
engraftment was achieved by 122 of 133 patients
with advanced-stage disease (91.7%), compared with
209 of 215 those with early-stage disease (97.2%),
with respective actuarial probabilities of 91.28% 6
2.58%, and 96.86% 6 1.28% (P 5 .007). The median
time to achieve an untransfused platelet count .
20,000/mL was significantly shorter in patients with
early disease than those with advanced disease (15
days [range, 7 to 356 days] vs 18 days [range, 8 to
258 days]; P 5 .016).
In the univariate analysis (Table 2), 5 other factors
were found to be associated with platelet engraftment:
recipient age (P 5 .022), HLA match (P 5 .022), dis-
ease stage (P 5 .011), number of infused nuclear
cells/kg recipient weight (P 5 .045), and number in-
fused CD81 cells/kg recipient weight (P 5 .031).
Among those patients who achieved a sustained plate-
let count . 20,000/mL, an increased CD34 cell dose
was suggestively associated with a shorter time to
platelet recovery, although the strength of this associ-
ation was relatively weak (R5 -0.237; P\ .001). In ad-
dition, trends toward associations between sex (female
vs male; P 5 .084), time to transplantation after diag-
nosis (# 210 days vs. 210 days; P5 .056), and disease
stage (advanced stage vs early stage; P 5 .089) with
neutrophil engraftment were demonstrated (Table 2).
As reported previously [5], in this cohort of 348
patients, 198 developed cytomegalovirus (CMV)antigenemia, 126 developed hemorrhagic cystitis
(HC), and 10 developed hepatic veno-occlusive disease
(VOD). The cumulative incidences of these 3 compli-
cations were 56.90%6 2.70%, 36.20%6 2.60%, and
2.90%6 0.90%, respectively. The median time to on-
set was 35.5 days (range, 10 to 132 days) for CMV anti-
genemia, 33 days (range, 13 to 189 days) for HC, and
10.5 days (range, 6 to 15 days) for VOD. Univariate
analysis revealed a trend toward an association be-
tween CMV antigenemia and neutrophil engraftment
(P 5 .065). No association between CMV antigene-
mia, HC, or VOD and platelet engraftment was
observed (Table 2).Multivariate Analysis
Multivariate analysis demonstrated no effects of
age, sex, HLA mismatch, ABO mismatch, CD31 and
CD341 cell dose, CMV antigenemia, HC, or VOD
on the incidence of neutrophil engraftment. Consider-
ing the factors affecting platelet engraftment, we at-
tempted to enter all variables with a P value\ .1 (ie,
recipient age, HLA mismatch, number of infused
CD81 cells/kg recipient weight, and number of in-
fused CD341 cells/kg recipient weight) into the re-
gression. In multivariate analysis, number of infused
CD341 cells (hazard ratio [HR] 5 1.695; 95% CI 5
1.361 to 2.112; P\ .0001) (Figure 1) and disease stage
(advanced vs early; HR 5 0.724; 95% CI 5 0.577 to
0.907; P5 .005) (Figure 2) were independently associ-
ated with an increased risk of platelet engraftment.
To explore whether the CD341 cell dose, as one of
the most important factors identified, is independent
of disease status, the patients were classified into 2
groups according to disease status. Multivariate Cox
regression analysis also demonstrated that higher
Figure 1. Effect of CD341 cell dose on the kinetics of platelet engraftment in patients with hematologic malignancies receiving T cell–replete blood and
marrow transplantation from HLA-mismatched/haploidentical related donors.
636 Biol Blood Marrow Transplant 15:632-638, 2009Y.-J. Chang et al.CD341 cell dose ($ 2.19  106/kg) in the allografts
was associated with faster platelet engraftment in
patients with early disease (HR 5 1.573; 95%
CI 5 1.192 to 2.077; P 5 .001) and those with ad-
vanced disease (HR 5 1.876; 95% CI 5 1.294 to
2.720; P\ .0001).DISCUSSION
In this study, all patients achieved neutrophil en-
graftment within 14 days of transplantation. A few pa-
tients still experienced delays in platelet recovery,
however, necessitating more transfusion support and
putting them at increased risk for bleeding. Our find-
ings indicate that the CD341 cell dose is critical to suc-
cessful platelet engraftment. Several previous studies
have demonstrated a strong inverse correlation be-
tween CD341 cell dose and platelet engraftment ki-
netics, with an estimated threshold minimum of no
less than 5  106cells/kg recipient weight for rapid
platelet recovery [24-27]. Our findings are consistentFigure 2. Effect of disease stage at transplantation on the kinetics of platelet
replete blood and marrow transplantation from HLA-mismatched/haploidentiwith those of some previous studies [25,26] but suggest
that a threshold CD341 cell dose of 2.19  106/kg is
sufficient for rapid platelet engraftment. Our lower
threshold CD341 cell dose than those reported by
other researchers may result from our strict gating
for the CD341 cell assay [28]. Another potential expla-
nation may be linked to our use of a significantly lower
rhG-CSF dose (5 mg/kg/day vs 10 to 15 mg/kg/day)
[29,30].
We also found significantly delayed platelet recov-
ery in the recipients with advanced-stage disease com-
pared with those with early-stage disease (actuarial
probability: 91.28% 6 2.58% vs 96.86% 6 1.28%;
P 5 .005), suggesting that disease stage is important
to successful platelet engraftment in this unmanipu-
lated HSCT setting [4,5]. To the best of our knowl-
edge, the patients with advanced-stage disease
typically received more cycles of chemotherapy than
those with early-stage disease, and some may have un-
dergone transplantation while in relapse; these
patients could have more minimal residual diseaseengraftment in patients with hematologic malignancies receiving T cell–
cal related donors.
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damage from high-dose chemotherapy and leukemic
cells surviving after conditioning may contribute to
delayed platelet engraftment in these patients [32,33].
We failed to demonstrate an association between
CD341 cell dose and neutrophil engraftment. Nu-
merous studies in various transplantation settings
have investigated the relationships between clinical
outcomes and total graft cell dose, as well as doses
of individual cell subsets [34,35]. Regardless of cell
source, an almost consistent finding has been an asso-
ciation between higher CD341 cell dose and more
rapid neutrophil engraftment [9,11,24,36]. Results
from these studies suggest that a relatively low
CD341 cell dose (ie, 2 to 4  106 cells/kg recipient
weight) is the minimum required for rapid engraft-
ment [36]. These considerations, along with our insti-
tutional target of $ 2  106 CD341 cells/kg, likely
explain much of the poor correlation between engraft-
ment and CD341 cell dose in the present study.
Moreover, the effects of CD31 cells on engraftment
have been demonstrated previously [37-39]. Urbano-
Ispizua et al. [39] studied 257 patients in T cell–
depleted transplantation settings and found that the
number of CD31 cells in the inoculum (with a thresh-
old of 0.2  106 cells/kg) is the most critical factor in
maintaining sustained engraftment. Our significantly
higher CD31 cell counts (median, 1.64  108cells/
kg) in the allografts may be sufficient to maintain en-
graftment even in haploidentical settings. In addition,
the differences in engraftment kinetics between plate-
lets and neutrophils may account, at least in part, for
our finding of an association between CD341 cell
dose and platelet engraftment, but not neutrophil en-
graftment.
Megadoses of CD341 cells have been used to over-
come graft rejection in HSCT with ex vivo T cell de-
pletion [40,41]. In our protocol, CD341 cell dose in
the mixture grafts of G-PB and G-BM is an important
factor affecting neutrophil and platelet engraftment,
although other factors, including ATG, and CD31
cell dose in the mixture grafts of G-PB and G-BM,
also may contribute to hematopoietic reconstitution.
Taken together, our findings and those of others
[7,9,11,14,36] suggest almost universally that CD341
cell dose is a key factor in hematopoietic engraftment
not only in HLA-matched/haploidentical HSCT
protocols [14,36,40,42], but also in autologous HSCT
settings [7,9].
In summary, our results demonstrate that a CD341
cell dose in the inoculum\2.19 106cells/kg is a crit-
ical factor associated with delayed platelet engraftment
after unmanipulatedHSCT.AhigherCD341 cell dose
is desirable to ensure rapid platelet engraftment, espe-
cially in patients with advanced-stage disease, because
this is also associated with delayed platelet recovery
in our transplantation setting.ACKNOWLEDGMENTS
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